132 related articles for article (PubMed ID: 36221796)
1. Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints.
Gonzalez-Farre B; Ramis-Zaldivar JE; Castrejón de Anta N; Rivas-Delgado A; Nadeu F; Salmeron-Villalobos J; Enjuanes A; Karube K; Balagué O; Cobo F; Kelleher N; Victoria I; Veloza L; Teixido C; Giné E; Lopez-Guerra M; Quintanilla-Martinez L; Lopez-Guillermo A; Salaverria I; Campo E
Am J Surg Pathol; 2023 Feb; 47(2):202-211. PubMed ID: 36221796
[TBL] [Abstract][Full Text] [Related]
2. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.
Shimada K; Yoshida K; Suzuki Y; Iriyama C; Inoue Y; Sanada M; Kataoka K; Yuge M; Takagi Y; Kusumoto S; Masaki Y; Ito T; Inagaki Y; Okamoto A; Kuwatsuka Y; Nakatochi M; Shimada S; Miyoshi H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Shiozawa Y; Nannya Y; Okabe A; Kohno K; Atsuta Y; Ohshima K; Nakamura S; Ogawa S; Tomita A; Kiyoi H
Blood; 2021 Mar; 137(11):1491-1502. PubMed ID: 33512416
[TBL] [Abstract][Full Text] [Related]
3.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
4. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.
Gupta GK; Jaffe ES; Pittaluga S
Histopathology; 2019 Aug; 75(2):282-286. PubMed ID: 30938862
[TBL] [Abstract][Full Text] [Related]
5.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
[TBL] [Abstract][Full Text] [Related]
7. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
8. Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.
Sakakibara A; Inagaki Y; Imaoka E; Sakai Y; Ito M; Ishikawa E; Shimada S; Shimada K; Suzuki Y; Nakamura S; Satou A; Kohno K
Pathol Int; 2019 Mar; 69(3):148-154. PubMed ID: 30688388
[TBL] [Abstract][Full Text] [Related]
9. Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.
Sakakibara A; Inagaki Y; Imaoka E; Ishikawa E; Shimada S; Shimada K; Suzuki Y; Nakamura S; Satou A; Kohno K
J Clin Exp Hematop; 2018 Mar; 58(1):32-35. PubMed ID: 29415979
[TBL] [Abstract][Full Text] [Related]
10. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
11. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
13. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
16. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Lu F; Zhao Y; Pang Y; Ji M; Sun Y; Wang H; Zou J; Wang Y; Li G; Sun T; Li J; Ma D; Ye J; Ji C
Cancer Lett; 2021 Jan; 497():178-189. PubMed ID: 33091534
[TBL] [Abstract][Full Text] [Related]
18. Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Shimada K; Kiyoi H
Cancer Sci; 2021 Oct; 112(10):3953-3961. PubMed ID: 34327781
[TBL] [Abstract][Full Text] [Related]
19. Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study.
Patel N; Slack GW; Bodo J; Ben-Neriah S; Villa D; Durkin L; Socha D; Steidl C; Hsi ED
Am J Clin Pathol; 2022 Apr; 157(4):578-585. PubMed ID: 34724028
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
